Blepharoplasty Prior Authorization in Ophthalmology ASCs: What CMS Is Requiring and How to Avoid Denials

What Are the New Blepharoplasty Prior Authorization Requirements for Ophthalmology ASCs?

As of January 2026, CMS requires prior authorization for blepharoplasty, blepharoptosis repair, brow ptosis repair, and botulinum toxin injections performed in ambulatory surgical centers across 10 states under a five-year demonstration project. The program targets CPT codes 15820 through 15823, 67900 through 67908, and several botulinum toxin codes including 64612 and 64615. ASCs that bypass prior authorization face mandatory prepayment medical review on those claims. The same documentation requirements that have applied to hospital outpatient departments since 2020 now extend to the ASC setting.

Ten states are live now: California, Florida, Georgia, Maryland, New York, Pennsylvania, and Tennessee began January 19, 2026. Texas, Arizona, and Ohio followed on February 16, 2026.

Prior authorization is technically voluntary but skipping it triggers prepayment review: If you do not submit a prior authorization request before performing a covered procedure, the MAC will hold and review the claim before releasing payment.

The same rules may expand under the 2027 OPPS/ASC proposed rule: CMS-1850-P, released July 2, 2026, proposes a 2.4 percent ASC payment update and continues the framework that supports expanding prior authorization programs into surgical centers.

Why CMS Expanded Prior Authorization to ASCs

Prior authorization for blepharoplasty and botulinum toxin injections in hospital outpatient departments has been in effect since July 1, 2020, under the CY 2020 OPPS/ASC final rule (CMS-1717-FC). CMS launched the program because it identified these services as vulnerable to improper payment, specifically cosmetic procedures billed as medically necessary. The hospital outpatient program worked. Utilization in that setting declined. But CMS data showed that utilization of the same procedures simultaneously increased in ASCs across the country, which strongly suggested the volume was migrating to the lower-oversight setting rather than actually declining.

In September 2025, CMS announced a five-year ASC prior authorization demonstration to close that gap. The demonstration went live in two phases across 10 states that together account for a large share of Medicare ASC volume. For ophthalmology practices that perform functional eyelid surgery or use botulinum toxin for conditions like blepharospasm, this means a procedural step that was previously only a hospital outpatient concern is now an ASC concern.

The shift matters because many ophthalmologists who moved oculoplastic procedures from the HOPD to the ASC specifically to avoid the hospital prior authorization burden are now subject to the same requirement in the facility they moved to. If your practice performs these procedures in an ASC in any of the 10 demonstration states, the prior authorization requirement applies regardless of your documentation quality or denial history.

Which Ophthalmology CPT Codes Require Prior Authorization

The CMS ASC prior authorization demonstration covers the same procedure categories as the hospital outpatient program. For ophthalmology, two categories apply directly: eyelid surgery and botulinum toxin injections. Here are the CPT codes subject to prior authorization when performed in an ASC in a demonstration state.

Blepharoplasty, blepharoptosis repair, and brow ptosis repair:

CPT 15820 (blepharoplasty, lower eyelid), CPT 15821 (blepharoplasty, lower eyelid with extensive herniated fat pad), CPT 15822 (blepharoplasty, upper eyelid), CPT 15823 (blepharoplasty, upper eyelid with excessive skin weighting down lid), CPT 67900 (repair of brow ptosis), CPT 67901 through 67904 (repair of blepharoptosis by various techniques), CPT 67906 (superior rectus technique with fascial sling), and CPT 67908 (conjunctivo-tarso-Muller’s muscle-levator resection).

Botulinum toxin injections:

CPT 64612 (chemodenervation of muscles innervated by facial nerve, such as for blepharospasm) and CPT 64615 (chemodenervation of muscles innervated by facial, trigeminal, cervical spinal, and accessory nerves, bilateral, such as for chronic migraine). Associated drug codes J0585 through J0588 are also included in the authorization process.

Notably, cataract surgery (CPT 66984), retinal procedures, and glaucoma laser codes are not included in this program. The prior authorization requirement is limited to the five service categories that CMS considers vulnerable to cosmetic misuse: blepharoplasty, botulinum toxin, panniculectomy, rhinoplasty, and vein ablation. But for practices with an oculoplastic component, the blepharoplasty and Botox categories represent a meaningful share of ASC volume.

Which States Are Affected

The five-year demonstration is running in 10 states. Phase 1 launched January 19, 2026 in California, Florida, Tennessee, Pennsylvania, Maryland, Georgia, and New York, with prior authorization requests accepted starting January 5, 2026. Phase 2 launched February 16, 2026 in Texas, Arizona, and Ohio, with requests accepted starting February 2, 2026.

If your ASC is located outside these 10 states, the demonstration does not currently apply to you, though CMS has the authority to expand it. If your practice operates ASCs in multiple states, you may need to manage two different workflows: prior authorization in demonstration states and standard claim submission everywhere else. For a broader look at how documentation requirements and coding accuracy affect your full revenue cycle, see our ophthalmology medical billing and coding guideline.

What Documentation You Need for Blepharoplasty Prior Authorization

The prior authorization request does not create new documentation requirements. It requires the same clinical information that Medicare already expects to support medical necessity for functional eyelid surgery. But it requires that documentation to be submitted and reviewed before the procedure, not after. Here is what the Medicare Administrative Contractor expects when you submit a prior authorization request for blepharoplasty or blepharoptosis repair.

The MAC will look for documented subjective patient complaints that justify functional surgery, such as vision obstruction or inability to perform daily tasks. You need signed clinical notes supporting a decrease in peripheral vision or upper field vision causing the functional deficit. The request should include signed physician documentation of functional impairment and a recommendation for surgery. Photographs of the eyelids are required, including frontal views showing the lid position, and for upper lid procedures, photos demonstrating redundant skin on the upper eyelashes. If visual field testing has been performed, include the full dictation and interpretation of the results. The specific visual field level that applies is CPT 92081 or 92082, not the extended visual field (92083), though our guide to CPT 92083 billing requirements covers when the extended test is separately reportable.

For botulinum toxin injections, the documentation must demonstrate that the injection is being performed for a medically necessary condition such as blepharospasm, hemifacial spasm, or chronic migraine, not for cosmetic purposes. The diagnosis code on the prior authorization request must align with the clinical documentation.

Local coverage determinations vary by MAC. The AAO maintains a current index of LCD requirements for blepharoplasty at aao.org/lcds. Check your MAC’s specific requirements before submitting, because the documentation checklist can differ on details like whether MRD1 measurements are required versus optional.

What Happens If You Skip Prior Authorization

The CMS ASC demonstration describes prior authorization as voluntary. That word is misleading. If you elect not to submit a prior authorization request before performing a covered procedure, the claim is automatically flagged for prepayment medical review. That means the MAC holds the claim, requests the same documentation you would have submitted through the PA process, and reviews it before releasing payment.

The practical difference between submitting a PA request upfront and facing prepayment review afterward is timing and cash flow. A prior authorization request submitted before the procedure, if approved, results in a unique tracking number (UTN) that travels with the claim and signals the MAC that the documentation has already been reviewed. An approved PA is generally valid for 120 days, and the claim processes at normal speed.

If you skip the PA and the claim goes to prepayment review, the MAC may request additional documentation, and payment is delayed until the review is complete. If the documentation does not support medical necessity, the claim is denied before it is ever paid, which is a harder position to appeal from than a PA denial issued before the procedure was performed. In our experience matching providers with billing partners, practices that treat the prior authorization step as optional discover the cash flow impact once a batch of blepharoplasty claims sits in prepayment review for 30 to 60 days.

How This Connects to the 2027 OPPS/ASC Proposed Rule

On July 2, 2026, CMS released the CY 2027 Hospital OPPS and ASC Payment System proposed rule (CMS-1850-P). The rule proposes a 2.4 percent ASC payment rate increase for facilities that meet quality reporting requirements, based on a 3.2 percent market basket increase offset by a 0.8 percentage point productivity adjustment. CMS also proposes extending the hospital market basket update as the ASC update factor through CY 2027.

The 2027 rule does not propose expanding the ASC prior authorization demonstration to additional states or procedures at this time. However, it continues the policy direction that led to the demonstration in the first place: CMS is actively monitoring procedure migration from hospitals to ASCs and expanding oversight tools to follow that volume. The proposed rule also includes expanded site-neutral payment policies and additional prior authorization requirements for other hospital outpatient services, which signals the broader regulatory trajectory.

Separately, the CY 2027 Physician Fee Schedule proposed rule (CMS-1848-P) proposes a same-day E/M payment reduction that would affect ophthalmology across all settings. Between the PFS same-day billing change and the ASC prior authorization requirements, practices that perform oculoplastic procedures face compliance pressure from two directions simultaneously. For a detailed breakdown of how the fee schedule changes affect ophthalmology reimbursement, see our revenue cycle management guide.

Who Handles the Prior Authorization Submission

CMS allows either the physician’s office or the ASC facility to submit the prior authorization request to the MAC. In practice, the physician’s office almost always handles it, because the clinical documentation supporting medical necessity, including the patient’s functional complaints, photographs, visual field results, and examination notes, lives in the physician’s medical record. The ASC typically has the operative and anesthesia records but not the pre-operative workup that the MAC needs to evaluate medical necessity.

This creates a coordination challenge. The physician’s office submits the PA request and receives the UTN. That UTN must then be communicated to the ASC, which includes it on the facility claim. If the UTN is not on the claim, the MAC treats the claim as though no prior authorization was obtained, and it goes to prepayment review. The most common issue we see providers run into is a breakdown in this handoff: the physician’s office obtains the approval, the UTN is not transmitted to the ASC billing team, and the facility claim is delayed or denied.

When prior authorization is approved, the approval is generally valid for 120 days. If the procedure is not performed within that window, the authorization expires and must be resubmitted. Practices that schedule blepharoplasty procedures several months out should track the PA expiration date alongside the surgical date to avoid performing a procedure after the authorization has lapsed.

Common Prior Authorization Mistakes in Ophthalmology

Across the billing companies we vet, several patterns repeat with blepharoplasty prior authorization.

Submitting photographs that do not meet the MAC’s requirements. Each MAC has specific photography standards, and some require both frontal and oblique views while others accept frontal only. Submitting the wrong set delays the PA decision.

Failing to include visual field testing when the LCD requires it. Not every MAC requires visual fields for every blepharoplasty CPT code, but when the LCD specifies visual field documentation, omitting it results in a non-affirmation. For the visual field codes that apply, the appropriate level for prior authorization documentation is CPT 92081 or 92082, which tests different degrees of field extent.

Mixing cosmetic and functional documentation. If the patient is having both a cosmetic lower blepharoplasty and a functional upper blepharoplasty, the PA request must clearly separate the two. Only the functional procedure is submitted for Medicare coverage. Including cosmetic language in the functional PA documentation gives the reviewer a reason to question the medical necessity of the entire request.

Not checking whether both blepharoplasty and blepharoptosis repair require separate documentation. When both procedures are planned for the same patient, such as CPT 15823 and CPT 67904, each must be individually documented with its own medical necessity criteria. The MAC will not infer that the documentation for one procedure supports the other.

Letting the UTN expire before surgery. The 120-day approval window does not reset. If the procedure is rescheduled past the expiration date, the authorization is void and the practice must resubmit.

In-House vs. an Ophthalmology Billing Partner Under PA Requirements

Prior authorization adds a distinct administrative layer that not every in-house billing team is equipped to manage. The PA workflow requires tracking which states require authorization, which CPT codes are covered, which MAC handles the request, what documentation each MAC expects, how to submit electronically through esMD, how to track the UTN, and how to coordinate the approval between the physician’s office and the ASC. For a single-surgeon practice that performs a handful of functional blepharoplasties per month, this may be manageable. For a multi-provider oculoplastic group performing these procedures weekly across different facilities and states, the compliance burden scales quickly.

A billing company with direct ophthalmology experience has already built the prior authorization workflow into its standard operating procedures. It tracks LCD requirements by MAC, manages the UTN handoff between the physician’s office and the ASC, monitors authorization expiration dates, and handles prepayment review responses when claims are flagged. These are the operational details that separate a billing partner who knows oculoplastic coding from a generalist who discovers the PA requirement when the first claim is held.

This is exactly the scenario Tim Daniels, Director of Strategic Accounts at Billing Service Quotes, weighs when evaluating whether a practice’s billing operation can absorb a new compliance layer without losing recoverable revenue. If your current team cannot tell you how many of your ASC blepharoplasty claims required prior authorization last quarter, or how many were sent to prepayment review, those are signals that the workflow is not being managed. If you are evaluating your options, our guide on how to find the right ophthalmology medical billing service covers what to look for in a billing partner.

Frequently Asked Questions

Next Steps

If your ASC is in one of the 10 demonstration states, confirm that your blepharoplasty and botulinum toxin workflows include a prior authorization step before scheduling. Check your MAC’s LCD requirements at aao.org/lcds to ensure your documentation package matches what the reviewer expects.

If your billing team is not currently tracking prior authorization submissions, UTN numbers, and authorization expiration dates for ASC eyelid procedures, now is the time to build that workflow or bring in a billing partner who already has it in place.